A number of other analysts also recently issued reports on AIMT. Zacks Investment Research raised Aimmune Therapeutics from a sell rating to a hold rating in a research note on Thursday, November 7th. Piper Jaffray Companies set a $60.00 price objective on Aimmune Therapeutics and gave the stock a buy rating in a research note on Wednesday, October 9th. Royal Bank of Canada reduced their price objective on Aimmune Therapeutics to $50.00 and set an outperform rating on the stock in a research note on Friday, August 9th. Wedbush reaffirmed a buy rating on shares of Aimmune Therapeutics in a research note on Thursday, October 31st. Finally, Stifel Nicolaus raised Aimmune Therapeutics to a positive rating in a research note on Monday, September 16th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Aimmune Therapeutics currently has a consensus rating of Buy and an average price target of $43.11.
Shares of AIMT opened at $27.92 on Friday. The business’s 50 day moving average is $27.04 and its 200 day moving average is $22.08. The company has a market capitalization of $1.75 billion, a PE ratio of -7.61 and a beta of -0.03. Aimmune Therapeutics has a 12-month low of $16.95 and a 12-month high of $29.68. The company has a current ratio of 4.64, a quick ratio of 4.64 and a debt-to-equity ratio of 0.33.
In other news, CFO Eric Bjerkholt acquired 1,550 shares of Aimmune Therapeutics stock in a transaction on Wednesday, September 18th. The shares were acquired at an average price of $22.57 per share, with a total value of $34,983.50. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 13.75% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD increased its position in shares of Aimmune Therapeutics by 11.4% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 5,246,604 shares of the biotechnology company’s stock valued at $109,234,000 after purchasing an additional 535,072 shares during the last quarter. Point72 Asset Management L.P. bought a new position in shares of Aimmune Therapeutics during the 2nd quarter valued at approximately $10,835,000. Eventide Asset Management LLC increased its position in shares of Aimmune Therapeutics by 11.1% during the 3rd quarter. Eventide Asset Management LLC now owns 3,084,000 shares of the biotechnology company’s stock valued at $64,579,000 after purchasing an additional 309,000 shares during the last quarter. Millennium Management LLC bought a new position in shares of Aimmune Therapeutics during the 3rd quarter valued at approximately $5,338,000. Finally, Nuveen Asset Management LLC bought a new position in shares of Aimmune Therapeutics during the 2nd quarter valued at approximately $3,969,000. 81.82% of the stock is currently owned by institutional investors and hedge funds.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Featured Story: Rule of 72
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.